APA (7th ed.) Citation

AM, K., CJ, D., JS, H., GJ, J., PK, K., DR, L., . . . FG, H. (2026). Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology, 133(4), 451. https://doi.org/10.1016/j.ophtha.2025.12.011

Chicago Style (17th ed.) Citation

AM, Khanani, et al. "Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial." Ophthalmology 133, no. 4 (2026): 451. https://doi.org/10.1016/j.ophtha.2025.12.011.

MLA (9th ed.) Citation

AM, Khanani, et al. "Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial." Ophthalmology, vol. 133, no. 4, 2026, p. 451, https://doi.org/10.1016/j.ophtha.2025.12.011.